Business
Arius announces first quarter fiscal 2007 financial results
Arius announces first quarter fiscal 2007 financial results.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, April 12 /CNW/ - ARIUS Research Inc., ("ARIUS" or the "Company")\n(TSX: ARI), a biotechnology company discovering and developing the next wave\nof antibody therapeutics, today announced its financial and operational\nresults for the first quarter, ended February 28, 2007.\n\n\n"Our primary focus for 2007 will be to advance ARIUS-originated\nantibodies towards clinical development," said Dr. David Young, President and\nCEO. "During the quarter, we focused on moving our three lead antibody\nprograms into pre-IND enabling studies in preparation for toxicology studies\nlater in 2007 and human clinical trials planned for 2008. We also continued to\nsupport our numerous research partnerships, delivering novel antibody\ncandidates to Takeda during the quarter and receiving a positive progress\nreport from Genentech."\n\n\nDuring the first quarter ended February 28, 2007, ARIUS achieved the\nfollowing:\n\n\n- Genentech, Inc. reported positive progress on the CD63 antibody\n program ARIUS licensed to Genentech in March 2006, including\n conducting preclinical studies in a variety of cancer indications in\n order to move the lead antibody towards the clinic;\n- Demonstrated significant positive results in animal models for the\n CD44 antibody in liver cancer, a new indication for this anti-cancer\n stem cell targeted antibody program;\n- Successfully developed and delivered novel antibodies to Takeda\n Pharmaceutical Company Limited for evaluation under the research\n agreement with Takeda; and\n- Received notice from the United States Patent and Trademark Office of\n two patent grants for antibodies within the CD63 program.\n\n\nCD44 Program:\n\n\nThe Company engaged a manufacturer to begin process development and\nmanufacturing for its lead anti-CD44 monoclonal antibody under Current Good\nManufacturing Practices (cGMP). The Company expects to perform pre-clinical\ntoxicology studies in the second half of calendar 2007 in preparation for\nfiling a Phase I Investigational New Drug (IND) application in the first half\nof 2008.\n\n\nCD59 Program:\n\n\nThe Company selected an antibody to this target for preclinical\ndevelopment based on potent tumor growth inhibition in several cancer types.\nThe Company has engaged Antitope Inc. to humanize the molecule and develop\nexpression cell l...